Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2448-2458

  Peck, Amy R ^a,b,c,d,e,f   Witkiewicz, Agnieszka K ^a,b,c,d,e,f   Liu, Chengbao ^a,b,c,d,e,f   Stringer, Ginger A ^a,b,c,d,e,f   Klimowicz, Alexander C ^a,b,c,d,e,f   Pequignot, Edward ^a,b,c,d,e,f   Freydin, Boris ^a,b,c,d,e,f   Tran, Thai H ^a,b,c,d,e,f   Yang, Ning ^a,b,c,d,e,f   Rosenberg, Anne L ^a,b,c,d,e,f   Hooke, Jeffrey A ^a,b,c,d,e,f   Kovatich, Albert J ^a,b,c,d,e,f   Nevalainen, Marja T ^a,b,c,d,e,f   Shriver, Craig D ^a,b,c,d,e,f   Hyslop, Terry ^a,b,c,d,e,f   Sauter, Guido ^a,b,c,d,e,f   Rimm, David L ^a,b,c,d,e,f   Magliocco, Anthony M ^a,b,c,d,e,f   Rui, Hallgeir ^a,b,c,d,e,f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MDR Global Systems   (United States)

^c TOM BAKER CANCER CENTRE   (Canada)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STAT5 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 79959309120     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3552     Document Type: Article

References (45)

1. Gouilleux F, Wakao H, Mundt M, et al: Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. Embo J 13:4361-4369, 1994 (Pubitemid 24295208)
2. Liu X, Robinson GW, Wagner KU, et al: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11:179-186, 1997 (Pubitemid 27081895)
3. Teglund S, McKay C, Schuetz E, et al: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93:841-850, 1998 (Pubitemid 28257589)
4. Xie J, LeBaron MJ, Nevalainen MT, et al: Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J Biol Chem 277:14020-14030, 2002 (Pubitemid 34968011)
5. Wagner KU, Krempler A, Triplett AA, et al: Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 24:5510-5520, 2004 (Pubitemid 38738182)
6. Nevalainen MT, Xie J, Bubendorf L, et al: Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 16:1108-1124, 2002 (Pubitemid 34478547)
7. Iavnilovitch E, Groner B, Barash I: Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1:32-47, 2002 (Pubitemid 36330209)
8. Humphreys RC, Hennighausen L: Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10:685-694, 1999 (Pubitemid 29511026)
9. Ren S, Cai HR, Li M, et al: Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21:4335-4339, 2002 (Pubitemid 34753841)
10. Sultan AS, Xie J, Lebaron MJ, et al: Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24:746-760, 2005 (Pubitemid 40216084)
11. Nouhi Z, Chughtai N, Hartley S, et al: Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 66: 1824-1832, 2006
12. Sultan AS, Brim H, Sherif ZA: Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelialmesenchymal transition. Cancer Sci 99:272-279, 2008 (Pubitemid 351228480)
13. Nevalainen MT, Xie J, Torhorst J, et al: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053-2060, 2004 (Pubitemid 41095137)
14. Bratthauer GL, Strauss BL, Tavassoli FA: STAT 5a expression in various lesions of the breast. Virchows Arch 448:165-171, 2006 (Pubitemid 43237882)
15. Yamashita H, Nishio M, Ando Y, et al: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13:885-893, 2006 (Pubitemid 44763264)
16. Cotarla I, Ren S, Zhang Y, et al: Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108:665-671, 2004 (Pubitemid 38076397)
17. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327, 2002 (Pubitemid 35373567)
18. McCabe A, Dolled-Filhart M, Camp RL, et al: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808-1815, 2005
19. Kang JY, Dolled-Filhart M, Ocal IT, et al: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63:1101-1105, 2003 (Pubitemid 36278444)
20. Giltnane JM, Moeder CB, Camp RL, et al: Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 115:2400-2409, 2009
21. Dolled-Filhart M, Ryden L, Cregger M, et al: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12:6459-6468, 2006 (Pubitemid 44799719)
22. Gustavson MD, Bourke-Martin B, Reilly DM, et al: Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated quantitative analysis. Appl Immunohistochem Mol Morphol 17:329-337, 2009
23. LeBaron MJ, Crismon HR, Utama FE, et al: Ultrahigh density microarrays of solid samples. Nat Methods 2:511-513, 2005 (Pubitemid 41131156)
24. Camp RL, Dolled-Filhart M, Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252-7259, 2004 (Pubitemid 39487712)
25. Punt CJ, Buyse M, Kohne CH, et al: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998-1003, 2007 (Pubitemid 47232601)
26. Prat A, Baselga J: The role of hormonal therapy in the management of hormonal-receptorpositive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531-542, 2008
27. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
28. Clarke R, Leonessa F, Welch JN, et al: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71, 2001 (Pubitemid 32173107)
29. Schiff R, Massarweh SA, Shou J, et al: Crosstalk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-336S, 2004
30. De Laurentiis M, Arpino G, Massarelli E, et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748, 2005 (Pubitemid 41557193)
31. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
32. Nicholson S, Halcrow P, Sainsbury JR, et al: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810-814, 1988 (Pubitemid 19033402)
33. Arpino G, Green SJ, Allred DC, et al: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study Clin Cancer Res 10:5670-5676, 2004
34. Giltnane JM, Ryden L, Cregger M, et al: Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 25:3007-3014, 2007 (Pubitemid 47218046)
35. Osborne C, Schiff R, Arpino G: Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 14:458-465, 2005 (Pubitemid 41683567)
36. Stendahl M, Ryden L, Nordenskjold B, et al: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614-4618, 2006 (Pubitemid 44297812)
37. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
38. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
39. Filipits M, Rudas M, Heinzl H, et al: Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res 15:5888-5894, 2009
40. Porter PL, Barlow WE, Yeh IT, et al: P27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98:1723-1731, 2006 (Pubitemid 44942710)
41. Pohl G, Rudas M, Dietze O, et al: High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 21:3594-3600, 2003 (Pubitemid 46594051)
42. McCallum M, Baker C, Gillespie K, et al: A prognostic index for operable, node-negative breast cancer. Br J Cancer 90:1933-1941, 2004
43. Liu X, Robinson GW, Gouilleux F, et al: Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A 92:8831-8835, 1995
44. Dolled-Filhart M, Gustavson M, Camp RL, et al: Automated analysis of tissue microarrays. Methods Mol Biol 664:151-162, 2010
45. Camp RL, Dolled-Filhart M, King BL, et al: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63:1445-1448, 2003 (Pubitemid 36373626)